0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},m=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){Le(c)||u()})),c&&(m(),setInterval((function(){m()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};
NasdaqGS - Nasdaq Real Time Price • USD
Compare
At close: September 5 at 4:00 PM EDT
All SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
- MindMed to Participate in September Investor Conferences NEW YORK, September 04, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:
Business Wire • 2 days ago
MNMD -0.08% -
- MindMed Reports Second Quarter 2024 Financial Results and Business Updates NEW YORK, August 13, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended June 30, 2024, and provided a business update.
Business Wire • 24 days ago
MNMD -0.08% - Weekly Roundup on the Cannabis Sector & Psychedelic Sector Key Takeaways; Cannabis Sector Ascend Wellness reported Q2 revenue growth amid rising competition and profit decline. Green Thumb Industries surpassed Q2 expectations with 11% revenue growth. Trulieve beat Q2 sales estimates with 8% revenue growth. Ayr Wellness reported modest Q2 growth Verano Holdings reported a Q2 revenue decline, missing analysts’ expectations. Curaleaf reported 2% revenue […]
Market Exclusive • 24 days ago
MNMD -0.08% TCNNF GTBIF - Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering NEW YORK, August 09, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share, and, to certain investors, pre-funded warrants to purchase 1,428,775 common shares at a price of $6.999 per pre-funded warr
Business Wire • 27 days ago
MNMD -0.08% - Mind Medicine (MindMed) Inc. Announces Proposed Public Offering NEW YORK, August 09, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed.
Business Wire • 28 days ago
MNMD -0.08% -
- MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference NEW YORK, August 06, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Canaccord Genuity’s 44th Annual Growth Conference:
Business Wire • 30 days ago
MNMD -0.08% - MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update NEW YORK, August 06, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Tuesday, August 13, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the second quarter ended June 30, 2024.
Business Wire • last month
MNMD -0.08% - MindMed Appoints Stephanie fa*gan as Chief Corporate Affairs Officer NEW YORK, July 29, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie fa*gan, effective today, as Chief Corporate Affairs Officer. Ms. fa*gan will serve as a member of the executive team and will oversee public affairs and corporate communications for the Company.
Business Wire • last month
MNMD -0.08% - MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) NEW YORK, July 17, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, today announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering MM120 (lysergide). MM120 is currently in clinical development for adults with generalized anxiety disorder (GAD) and presents opportunities for treating a range of additional br
Business Wire • last month
MNMD -0.08% -
- MindMed to be Included in Russell 2000® and Russell 3000® Indexes NEW YORK, June 28, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective today.
Business Wire • 2 months ago
MNMD -0.08% - MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference NEW YORK, June 21, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024.
Business Wire • 2 months ago
MNMD -0.08% - MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) NEW YORK, June 20, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD.
Business Wire • 2 months ago
MNMD -0.08% - Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) 18% loss last week hit both individual investors who own 46% as well as institutions Key Insights Significant control over Mind Medicine (MindMed) by retail investors implies that the general public has...
Simply Wall St. • 2 months ago
MNMD -0.08% -
- MindMed to Participate in June Conferences NEW YORK, May 28, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:
Business Wire • 3 months ago
MNMD -0.08% - MindMed to Participate at May Investor Conferences NEW YORK, May 09, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
Business Wire • 3 months ago
MNMD -0.08% - New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US ATLANTA, May 09, 2024--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented new studies highlighting the significant impact of GAD in the US at ISPOR 2024, the leading global conference for health economics and outcomes research (HEOR) being held this week in Atlanta.
Business Wire • 3 months ago
MNMD -0.08% - MindMed Reports First Quarter 2024 Financial Results and Business Updates NEW YORK, May 08, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.
Business Wire • 3 months ago
MNMD -0.08% -
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York NEW YORK, May 04, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from MMED008, its Phase 2b study of MM120 (lysergide d-tartrate) in the treatment of GAD in adults. MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. The study was presented
Business Wire • 4 months ago
MNMD -0.08% - MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update NEW YORK, May 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the first quarter ended March 31, 2024.
Business Wire • 4 months ago
MNMD -0.08% - MindMed to Present at Upcoming May Medical Conferences NEW YORK, April 25, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
Business Wire • 4 months ago
MNMD -0.08%
Performance Overview
Trailing total returns as of 9/5/2024, which may include dividends or other distributions. Benchmark is S&P 500
| Return | MNMD | S&P 500 |
|---|---|---|
| YTD | +67.62% | +15.38% |
| 1-Year | +49.27% | +21.87% |
| 3-Year | -85.65% | +21.34% |
